目的 探究真实世界中程序性死亡蛋白1(Programmed Death Protein 1,PD-1)/程序性死亡蛋白配体1(Programmed Death Protein Ligand 1,PD-L1)抑制剂治疗对晚期非小细胞肺癌(Non-Small Cell Lung Cancer,NSCLC)二线及以上患者预后转归的影响.方法 选取2019年1月—2023年7月涟水县人民医院就诊的112例晚期NSCLC二线及以上患者为研究对象,依据治疗方法分为两组,每组56例,对照组接受二线及以上单药化疗,观察组接受PD-1/PD-L1抑制剂免疫治疗,对比两组生存质量、无进展生存期、总生存期及不良反应发生率.结果 化疗4个周期后,观察组生存质量评分显著高于对照组,差异有统计学意义(P<0.05).观察组无进展生存期、总生存期显著优于对照组,差异有统计学意义(P均<0.05).观察组不良反应发生率显著低于对照组,且观察组高血压发生人数显著少于对照组,差异有统计学意义(P均<0.05).结论 晚期NSCLC患者二线治疗中PD-1/PD-L1抑制剂免疫治疗能提升患者生存质量,降低其不良反应发生率.
Impact of PD-1/PD-L1 Inhibitor Immunotherapy on Prognostic Regres-sion in Patients with Advanced Non-small Cell Lung Cancer in Second Line and Above
Objective To investigate the effect of real-world programmed death protein 1(PD-1)/programmed death protein ligand 1(PD-L1)inhibitor therapy on the prognostic regression of patients with advanced non-small cell lung cancer(NSCLC)in the second line and above.Methods A total of 112 patients with second-line and above advanced NSCLC treated in Lianshui County People's Hospital from January 2019 to July 2023 were selected as the study ob-jects,and they were divided into two groups according to treatment methods,with 56 cases in each group.The control group received second-line or above single-drug chemotherapy,and the observation group received PD-1/PD-L1 in-hibitor immunotherapy.The quality of life,progression-free survival,overall survival and incidence of adverse reac-tions were compared between the two groups.Results After four cycles of chemotherapy,the quality of life score of ob-servation group was significantly higher than that of control group,and the difference was statistically significant(P<0.05).The progression-free survival and overall survival of the observation group were significantly better than those of the control group,and the differences were statistically significant(both P<0.05).The incidence of adverse reactions in observation group was significantly lower than that in control group,and the number of hypertensive patients in ob-servation group was significantly less than that in control group,and the differences were statistically significant(both P<0.05).Conclusion Immunotherapy with PD-1/PD-L1 inhibitors in the second-line treatment of advanced NSCLC patients can improve the quality of survival and reduce the incidence of adverse reactions.
NETL
NSTL
万方数据
维普
